Athos Capital’s LakeShore Biopharma Warrants LSBPW Stock Holding History

Athos Capital’s Portfolio LSBPW Stock Details LSBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-128,981	Closed	-$132K	–	46
2025 Q2	$132K	Hold	128,981	–	–	0.2%	28
2025 Q1	$32K	Hold	128,981	–	–	0.04%	39
2024 Q4	$45K	Hold	128,981	–	–	0.02%	37
2024 Q3	$88K	Hold	128,981	–	–	0.03%	35
2024 Q2	$84K	Hold	128,981	–	–	0.04%	36
2024 Q1	$93K	Hold	128,981	–	–	0.1%	40
2023 Q4	$67K	Hold	128,981	–	–	0.07%	38
2023 Q3	$103K	Sell	128,981 -21,018	-14%	-$1.1K	0.05%	51
2023 Q2	$207K	Hold	149,999	–	–	0.16%	60
2023 Q1	$240K	Buy	+149,999	New	+$22.7K	0.17%	74

Other funds holding LSBPW

HIM

HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return

Athos Capital's LSBPW Position: Q3 2025 in Review

Athos Capital sold out of LakeShore Biopharma Warrants (LSBPW) in Q3 2025, closing a stake of 128,981 shares — an estimated $132K sold.

Athos Capital first reported a position in LSBPW in Q1 2023 and held it in 10 quarters. The position peaked at $240K in Q1 2023. 3 funds tracked by Wall St. Rank hold LSBPW as of Q3 2025.

Athos Capital reported no remaining LakeShore Biopharma Warrants position as of Q3 2025 after selling out during the quarter.
Athos Capital sold 128,981 LakeShore Biopharma Warrants shares in Q3 2025, an estimated $132K.
Athos Capital first reported a position in LakeShore Biopharma Warrants in Q1 2023 and held it in 10 quarters.
Athos Capital's LakeShore Biopharma Warrants position peaked at $240K in Q1 2023.
3 funds tracked by Wall St. Rank held LakeShore Biopharma Warrants as of Q3 2025.

Based on Athos Capital's 13F filing for Q3 2025, filed 13 Nov 2025.